Milestone Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview

Milestone Pharmaceuticals

09/05/2025 15:04

Milestone Pharmaceuticals Inc MIST.OQ MIST.O is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Milestone Pharmaceuticals Inc is for a loss of 18 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $4.00​, above​ its last closing price of $1.20. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.14
-0.15
-0.20
Missed
-30.5
Sep. 30 2024
-0.18
-0.16
-0.14
Beat
14.3
Jun. 30 2024
-0.19
-0.19
-0.14
Beat
26.3​
Mar. 31 2024
-0.25
-0.26
-0.21
Beat
19.2
​​Dec. 31 2023
-0.30
-0.31
-0.32
Missed
-2.4
Sep. 30 2023
-0.38
-0.38
-0.35
Beat
8.4​
Jun. 30 2023
-0.38
-0.39
-0.37
Beat
4.1
Mar. 31 2023
-0.40
-0.40
-0.35
Beat
12.1

This summary was machine generated May 9 at 14:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)